Deloitte 2026 Diagnostic Report: How AI and Interoperability Are Driving the Diagnostics Industry Toward B2B2C

Title

Deloitte 2026 Diagnostic Report: How AI and Interoperability Are Driving the Diagnostics Industry Toward B2B2C

Introduction

The diagnostics industry is undergoing a structural shift that is less visible, but far-reaching. A recent study by the Deloitte Center for Health Solutions shows a clear perception gap between diagnostic manufacturers and healthcare providers regarding the “biggest friction points in the diagnostic process”: manufacturers are more focused on result interpretation, while hospitals and clinical institutions see test ordering as the main efficiency bottleneck.

This difference is not merely a process issue; it reflects a rewriting of the diagnostics industry’s business model. As consumer-driven testing, telemedicine, digital health platforms, and wearable devices continue to expand, diagnostics companies are being forced to move from being simple hardware or reagent suppliers to platform-based participants more deeply embedded in hospital EHR systems, clinical workflows, and patient-facing interfaces.

Industry Context

Deloitte’s study is based on research involving 50 diagnostic manufacturing executives, 50 healthcare provider executives, and 20 in-depth interviews. The report’s most important signal is that 62% of diagnostic manufacturing executives believe future growth will depend entirely on adopting a B2B2C model.

Here, B2B2C is not just a change in marketing language, but a shift in the business logic of diagnostics companies:

• They must serve traditional B-side customers such as hospitals, laboratories, and imaging centers
• They must also directly address increasingly proactive consumers and patients
• They must embed diagnostic products into clinical and non-clinical settings through AI Healthcare, interoperability, and automation tools

This trend is unfolding alongside the consumerization of healthcare. The study shows that 76% of healthcare provider respondents believe patient- and consumer-initiated testing demand will significantly reshape the diagnostics industry over the next three years. This means diagnostics are no longer confined to hospital labs or imaging centers, but are continuously triggered in homes, retail settings, tele-follow-up, and hybrid care networks.

At the same time, infrastructure problems are intensifying industry pressure. 74% of healthcare providers said their current data systems are completely fragmented and not integrated across the entire diagnostic chain. This fragmentation not only weakens clinical efficiency, but also makes it difficult for diagnostic data to form a closed loop between ordering, authorization, sampling, reporting, and follow-up management.

Key Developments

1. Manufacturers and hospitals disagree on what the “pain point” is

Deloitte points out that healthcare providers list test ordering as the biggest friction point in daily clinical workflows, while manufacturers are more inclined to invest resources in result interpretation.

This mismatch shows that the logic by which diagnostics companies have traditionally built products around “results” can no longer cover the real operational burden faced by hospitals.This misalignment shows that the logic diagnostic companies have long used to build products around “results” can no longer cover the real operational burden faced by hospitals. For hospitals, what actually consumes time is often not the result itself, but the upstream workflow:

• When to place the order
• Who approves it
• How to trigger prior authorization
• How to enter the test request into the EHR
• How to feed results back into the clinical workflow

This is also why diagnostic vendors increasingly need to include software, automation, and workflow services in their product mix, rather than selling only devices or test consumables.

2. Diagnostic companies are reassessing their customer structure

The study also found that manufacturers still mainly view hospital procurement departments and channel partners as key points of contact, but healthcare providers believe the people who truly influence long-term product use and clinical adoption are:

• Ordering physicians
• Laboratory directors
• Business line leaders

This means the traditional procurement-centered sales model is giving way to product design and go-to-market strategies centered on clinical adoption. For healthcare technology companies, future competition will no longer be only about “who can get onto the procurement list,” but “who can embed themselves in the daily workflows of physicians and labs.”

3. Interoperability is becoming a prerequisite for AI implementation

One of the most important findings in Deloitte’s study for the industry is that 74% of healthcare providers believe existing database systems are siloed across the diagnostic workflow. In such an environment, single-point AI tools are unlikely to create lasting value.

The report argues that if diagnostic vendors want to remain relevant in the era of home testing and wearable devices, they must:

• Embed AI natively into EHR workflows
• Automate prior authorization
• Provide consumers with more personalized, visualized data context

This effectively shifts the value definition of AI Healthcare from “algorithm accuracy” to “workflow integration capability.” In other words, competition in diagnostics is not just a contest of model performance, but also of interoperability, data pathways, and clinical integration capabilities.

4. Consumer-driven testing is reshaping the diagnostic entry point

The report notes that 92% of healthcare providers are already offering or exploring patient-initiated testing pathways, compared with 70% of manufacturers. This suggests that hospitals and clinical organizations are adjusting faster than some manufacturers in responding to consumerization trends.

This shift will affect value distribution across the entire Healthcare Industry:

• Home testing and retail testing add new traffic entry points
• Telehealth platforms need more connectable diagnostic services
• Healthcare SaaS and healthcare data management companies will benefit from higher demand for workflow digitization
• Traditional diagnostic equipment vendors, meanwhile, must close gaps in software and data capabilities

Market Implications

For the market, what this report conveys is not that “diagnostics will be replaced by AI,” but that “the profit pool of diagnostic companies will migrate toward workflow, integration, and consumer interaction.”

Which Companies May Benefit

1. HealthTech companies with EHR integration capabilities

Platforms that can connect diagnostics, prior authorization, reporting, and follow-up workflows are more likely to become part of the infrastructure layer for hospitals and laboratories.

2. Vendors offering healthcare automation and AI workflow tools

Especially in prior authorization, test triage, result summarization, and clinical documentation automation, the value of tools will expand from “improving efficiency” to “reducing friction and increasing adoption.”

3. Diagnostics and digital health companies with consumer reach

Companies that can turn test results into understandable, visual, and actionable information may find it easier to build stickiness within a B2B2C structure.

4. Healthcare data interoperability infrastructure providers

As system fragmentation is repeatedly emphasized, companies that can help hospitals, laboratories, and external platforms connect data will become key beneficiaries of the diagnostics digitalization upgrade.

Which Organizations Are Under Pressure

• Diagnostics manufacturers that still rely on traditional equipment sales
• Vendors that only cover the procurement side and lack clinical embedding capabilities
• In-house systems that cannot interoperate with EHRs, patient portals, and telehealth platforms

The risk for these organizations is not just slower growth, but being downgraded into “replaceable commoditized suppliers.”

Challenges And Risks

Although the B2B2C and AI-driven transformation of diagnostics looks directionally clear, real-world implementation still faces multiple obstacles.

1. Data fragmentation remains the core bottleneck

74% of healthcare providers believe current systems have failed to connect the full diagnostics workflow, which shows that interoperability is not a “technical detail,” but a prerequisite for industry upgrading. Without a unified data path, AI can only remain in isolated segments and will struggle to create network effects.

2. Workflow integration is harder than point solutions

Embedding AI into EHRs does not mean simply inserting a model interface. Hospital procurement, compliance, clinical validation, IT governance, and change management all extend deployment cycles. For vendors, product value must be designed in sync with clinical pathways and operational processes.

3. There is tension between consumer experience and clinical compliance

Consumers want faster, more intuitive, and more personalized diagnostic feedback, but healthcare institutions still need to ensure data accuracy, boundaries of responsibility, and information compliance. How to balance patient readability, clinical rigor, and regulatory requirements will determine whether the B2B2C model can scale sustainably.

4. The regulatory environment may redefine the boundaries of AI diagnostics

As the integration of AI Healthcare and Medical Devices deepens, regulators’ requirements for algorithm transparency, clinical validation, data security, and liability attribution may continue to rise. For vendors, regulation is not a peripheral variable, but part of the product architecture.

Future OutlookIn the next 3 to 5 years, the diagnostics industry will most likely evolve along three directions.

First, diagnostics vendors will shift from product sales to platform operations

The focus of competition will no longer be limited to testing itself, but to full-chain service capabilities spanning before, during, and after testing. Whether a company can integrate AI, interoperability, and automation into a platform will determine its position in the industry.

Second, hospitals and clinical institutions will become more reliant on embeddable diagnostic capabilities

As patient-initiated testing, home devices, and wearables become more widespread, hospitals are unlikely to completely exit the diagnostic entry point; instead, they will become more like coordination centers. Whoever can seamlessly integrate diagnostic capabilities into EHRs and clinical workflows will be more likely to achieve sustained usage.

Third, capital will continue to flow toward the “connective layer” rather than isolated tools

In healthcare technology investment, capital typically prefers infrastructure-like assets that are scalable, reusable, and can be embedded into existing systems. What will be worth watching in the future will not be a single AI model, but system-level solutions that connect diagnostics, data, payment, and clinical workflows.

Conclusion

The real value of Deloitte’s study is that it brings the core of future competition in the diagnostics industry back to the intersection of industry trends, technological evolution, capital direction, and regulatory change. For the healthcare technology industry, diagnostics is no longer just a laboratory testing activity, but a systemic market restructuring process driven jointly by AI, interoperability, and consumer participation.

SEO Description

Deloitte’s latest diagnostics study shows that 62% of manufacturers are betting on the B2B2C model. This article analyzes how AI Healthcare, interoperability, EHR workflow integration, and consumer-driven testing are reshaping the global healthcare technology industry.

Source URL

https://hitconsultant.net/2026/05/29/deloitte-2026-diagnostics-b2b2c-report/